Sfoglia per AUTORE
BEARZ A
Collezione AOU San Luigi di Orbassano

  

Items : 9

International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2022 Jan;33(1):57-66. doi: 10.1016/j.annonc.2021.09.017. Epub 2021 Oct 5.

2022
AO Cuneo
AOU San Luigi di Orbassano
AOU Città della Salute di Torino
AOU Novara

Scagliotti GV; Porcu L; Manegold C; Monica V; Wiest G; Irtelli L; Caffo O; Dickgreber NJ; Follador A; Pedrazzoli P; Bearz A; Griesinger F; Folprecht G; Schmid-Bindert G; Reck M; Chiari R; Gregorc V; Santo A; Morabito A; Schena M; Valmadre G; Borra G; Ceribelli A; Kropf-Sanchen C; Stoelben E; Cauchi C; Colantonio I; Geissler M; Meyer A; et alii...

Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2). in Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer / J Thorac Oncol. 2022 Dec;17(12):1404-1414. doi: 10.1016/j.jtho.2022.08.018. Epub 2022 Sep 10.

2022
AOU San Luigi di Orbassano

Ou SI; Nishio M; Ahn MJ; Mok T; Barlesi F; Zhou C; Felip E; de Marinis F; Kim SW; Pérol M; Liu G; Migliorino MR; Kim DW; Novello S; Bearz A; Garrido P; Mazieres J; Morabito A; Lin HM; Yang H; Niu H; Zhang P; Kim ES;

Corrigendum to "International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer": [Annals of Oncology 33 (2022) 57-66]. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2022 Apr;33(4):454. doi: 10.1016/j.annonc.2022.01.005. Epub 2022 Jan 25.

2022
AO Cuneo
AOU San Luigi di Orbassano
AOU Città della Salute di Torino
AOU Novara

Porcu L; Manegold C; Scagliotti GV; Monica V; Wiest G; Irtelli L; Dickgreber NJ; Caffo O; Pedrazzoli P; Bearz A; Folprecht G; Griesinger F; Follador A; Chiari R; Reck M; Morabito A; Santo A; Schmid-Bindert G; Gregorc V; Schena M; Valmadre G; Borra G; Ceribelli A; Kropf-Sanchen C; Stoelben E; Cauchi C; Colantonio I; Geissler M; Meyer A; et alii...

First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2020 May;130:155-167. doi: 10.1016/j.ejca.2020.02.023. Epub 2020 Mar 25.

2020
AO Ordine Mauriziano
AOU San Luigi di Orbassano

Baldessari C; Novello S; Bartoli G; Pizzutilo EG; Landi L; Dall'Olio FG; Toschi L; Sartori G; Ciccone LP; Garassino MC; Guaitoli G; Zanelli F; De Carlo E; Bearz A; Camerini A; Sala E; Migliorino MR; Cerea G; Ardizzoni A; Bennati C; Vita E; Del Conte A; Rossi S; Scotti V; Pilotto S; Cecere FL; Proto C; Berardi R; Mazzoni F; et alii...

Is multidisciplinary management possible in the treatment of lung cancer? A report from three Italian meetings. in La Radiologia medica / Radiol Med. 2020 Feb;125(2):214-219. doi: 10.1007/s11547-019-01094-w. Epub 2019 Oct 11.

2020
AOU San Luigi di Orbassano
AOU Città della Salute di Torino

Scotti V; Piperno G; Filippi AR; Tindara F; Ferrari K; Chiari R; Bearz A; Passaro A; Trovò M; Vattemi E; Bezzi M; Comin C; Andolina M; Badellino S; Ramella S; Buffoni L; Genovesi D; Giaj-Levra N; Bruni A; Borghetti P; Franceschini D;

NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial. in The Lancet. Oncology / Lancet Oncol. 2018 Jun;19(6):799-811. doi: 10.1016/S1470-2045(18)30193-1. Epub 2018 May 9.

2018
AOU San Luigi di Orbassano

Gregorc V; Gaafar RM; Favaretto A; Grossi F; Jassem J; Polychronis A; Bidoli P; Tiseo M; Shah R; Taylor P; Novello S; Muzio A; Bearz A; Greillier L; Fontana F; Salini G; Lambiase A; O'Brien M;

Ceritinib compassionate use for patients with crizotinib-refractory, anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer. in Future oncology (London, England) / Future Oncol. 2018 Feb;14(4):353-361. doi: 10.2217/fon-2017-0441. Epub 2017 Nov 14.

2018
AOU San Luigi di Orbassano

Metro G; Passaro A; Lo Russo G; Bonanno L; Giusti R; Gregorc V; Capelletto E; Martelli O; Cecere FL; Giannarelli D; Luciani A; Bearz A; Tuzi A; Scotti V; Tonini G; Galetta D; Carta A; Soto Parra H; Rebonato A; Morabito A; Chiari R; Metro G; Passaro A; Lo Russo G; Bonanno L; Giusti R; Gregorc V; Capelletto E; Martelli O; et alii...

BE-POSITIVE: Beyond progression after tyrosine kinase inhibitor in EGFR- positive non small cell lung cancer patients: Results from a multicenter Italian observational study. in Lung cancer (Amsterdam, Netherlands) / Lung Cancer. 2016 May;95:73-81. doi: 10.1016/j.lungcan.2016.02.011. Epub 2016 Feb 26.

2016
AOU San Luigi di Orbassano

Vavalà T; Follador A; Tiseo M; Galetta D; Morabito A; Di Maio M; Martelli O; Caffo O; Piovano PL; Cortinovis D; Zilembo N; Casartelli C; Banna GL; Ardizzoia A; Barzelloni ML; Bearz A; Genestreti G; Mucciarini C; Filipazzi V; Menis J; Rizzo E; Barbieri F; Rijavec E; Cecere F; Bria E; Spitaleri G; Rossi A; Novello S;

Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial. in The Lancet. Oncology / Lancet Oncol. 2014 Jun;15(7):713-21. doi: 10.1016/S1470-2045(14)70162-7. Epub 2014 May 13.

2014
AOU San Luigi di Orbassano

Gregorc V; Novello S; Lazzari C; Barni S; Aieta M; Mencoboni M; Grossi F; De Pas T; de Marinis F; Bearz A; Floriani I; Torri V; Bulotta A; Cattaneo A; Grigorieva J; Tsypin M; Roder J; Doglioni C; Levra MG; Petrelli F; Foti S; Viganò M; Bachi A; Roder H;